|

A Cohort Study in Newly Diagnosed MZL

RECRUITINGSponsored by Fudan University
Actively Recruiting
SponsorFudan University
Started2024-05-30
Est. completion2029-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06449885

Summary

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age≥ 18 years old; Male or female.
* Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors).
* Willing to provide biological samples required for the study, including blood samples and tumor tissue.
* Voluntarily join this study and sign the informed consent form.
* Willing to accept long-term follow-up.

Exclusion Criteria:

* Patients with HIV infection.
* Those who cannot come to the hospital regularly for follow-up.
* Those with comorbidities and speech impairment.

Conditions2

CancerMarginal Zone Lymphoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.